Targeted covalent inhibitors (TCIs) are established as powerful entities in drug discovery, but their application has so far mainly been limited to addressing cysteine. Competitive, residue-specific proteomics has been instrumental to streamline covalent drug discovery targeting cysteine. Several pr...
ORGANISM(S): Homo sapiens (Human) Staphylococcus aureus